Compazine Renal Dosing at CrCl 20 mL/min
No renal dose adjustment is required for Compazine (prochlorperazine) at a creatinine clearance of 20 mL/min, as prochlorperazine is primarily metabolized hepatically rather than renally cleared.
Dosing Recommendation
Prochlorperazine does not require dose modification based on renal function. The standard dosing regimens apply 1:
- For severe nausea/vomiting: 5-10 mg PO three to four times daily (maximum 40 mg/day in resistant cases)
- For non-psychotic anxiety: 5 mg PO three to four times daily (maximum 20 mg/day, duration ≤12 weeks)
- For psychotic disorders: Start 5-10 mg PO three to four times daily; may increase gradually to 100-150 mg/day in severe cases
Key Clinical Considerations
Elderly patients with renal impairment warrant special attention, not because of renal clearance issues, but due to increased susceptibility to hypotension and extrapyramidal reactions 1. In this population:
- Start at the lower end of the dosing range
- Titrate more gradually than in younger patients
- Monitor closely for adverse effects, particularly orthostatic hypotension and movement disorders
Important Contraindication
Prochlorperazine is contraindicated when used concomitantly with dofetilide in patients with CrCl 20-40 mL/min 2. Dofetilide dosing guidelines specifically list prochlorperazine as a contraindicated medication due to drug interaction concerns in renal impairment.
Rationale
Unlike many medications requiring renal dose adjustment at CrCl 20 mL/min, prochlorperazine undergoes extensive hepatic metabolism. The available evidence, including FDA labeling 1 and comprehensive renal dosing guidelines 3, does not include prochlorperazine among medications requiring renal dose modification. This absence from renal dosing tables is clinically significant—medications requiring adjustment are consistently listed with specific recommendations across these guidelines.
The primary safety concern at this level of renal function is not drug accumulation, but rather the patient's increased vulnerability to the medication's known adverse effects, particularly in elderly individuals who commonly have reduced creatinine clearance.